))
Antisense Oligonucleotides
Manage episode 312495036 series 3236617
Innhold levert av David Cunnington and SCN2A Australia. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av David Cunnington and SCN2A Australia eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work? To help gain a better understanding of ASOs and their role we talk to Dr Stanley Crooke, founder of Ionis.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Leave a review and subscribe via Apple Podcasts.
You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app
Links
- American Epilepsy Society meeting
- Summary of ASO presentations at AES
- Dr Ana Mignorance - @CNSDrugHunter on Twitter
- Ionis
- Webinar on ASO treatment for gain of function SCN2A
See omnystudio.com/listener for privacy information.
28 episoder
Del
